Prostaglandin analogs in the treatment of glaucoma

Seminars in Ophthalmology

Volumn 14, Issue 3, 1999, Pages 114-123

  Hejkal, Thomas W ^a,b   Camras, Carl B ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIPIVEFRINE; LATANOPROST; PHYSOSTIGMINE; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL; UNOPROSTONE ISOPROPYL ESTER;

CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EYE IRRITATION; GLAUCOMA; HUMAN; HYPEREMIA; KERATOPATHY; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; REVIEW; TOPICAL DRUG ADMINISTRATION; UVEITIS; VISUAL IMPAIRMENT;

EID: 0032863922     PISSN: 08820538     EISSN: None     Source Type: Journal    
DOI: 10.3109/08820539909061464     Document Type: Review

References (64)

1. Camras CB. Prostaglandins. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St. Louis, MO: Mosby; 1996:1449-1461.
2. Camras CB, Bito LZ, Toris CB. Prostaglandins and prostaglandin analogues. In: Zimmerman TJ, Kooner KS, Sharir M, et al eds. Textbook of Ocular Pharmacology. Philadelphia, PA: Lippincott; 1997:315-328.
3. Toris CB, Camras CB. Prostaglandins. A new class of aqueous outflow agents. In: Singh K, Zimmerman TJ, eds. Ophthalmology Clinics of North America. Philadelphia, PA: W.B. Saunders; 1997:335-355.
4. Starr MS. Further studies on the effect of prostaglandin on intraocular pressure in the rabbit. Exp Eye Res. 1971;11:170-177.
5. Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci. 1977;16:1125-1134.
6. Camras CB, Schumer RA, Marsk A, et al. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol. 1992; 110:1733-1738.
7. 2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707-716.
8. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389-402.
9. 2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res. 1995;61:649-657.
10. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304.
11. Toris CB, Camras CB, Yablonski ME, et al. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol. 1997;41: S69-S75.
12. Mishima HK, Kiuchi Y, Takamatsu M, et al. Circadian intraocular pressure management with latanoprost: Diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol. 1997;41:S139-S144.
13. Sakurai M, Araie M, Oshika T, et al. Effect of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol. 1991;35:156-165.
14. Stjernschantz J, Selén G, Ocklind A, et al. Effects of latanoprost and related prostaglandin analogues. In: Alm A, Weinreb R, eds. Uveoscleral Outflow. London: Mosby-Wolfe; 1998:57-72.
15. 2α effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 1995;36:2461-2465.
16. Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow. Surv Ophthalmol. 1997;41:S53-S59.
17. Lindsey JD, Weinreb RN. Effects of prostaglandins on uveoscleral outflow. In: Alm A, Weinreb R, eds. Uveoscleral Outflow. London: Mosby-Wolfe; 1998:41-55.
18. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
19. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology. 1995;102:1743-1752.
20. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126-137.
21. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12 week study. Arch Ophthalmol. 1996;114:929-932.
22. Patelska B, Greenfield DS, Liebmann JM, et al. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol. 1997;124:279-286.
23. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997;41:S105-S110.
24. Camras CB, Alm A, Watson PG, Stjernschantz J, the Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma therapy: Efficacy and safety after one year of treatment in 198 patients. Ophthalmology. 1996;103:1916-1924.
25. Camras CB, Wax MB, Ritch R, et al. Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol. Am J Ophthalmol. 1998;126:390-399.
26. Watson PG, the Latanoprost Study Group. Latanoprost. Two years' experience of its use in the United Kingdom. Ophthalmology. 1998;105:82-87.
27. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci. 1985;26:1315-1319.
28. Rácz P, Ruzsonyi MR, Nagy ZT, et al. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol. 1996;114:268-273.
29. Hayreh SS, Zimmerman MB, Podhajsky P, et al. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994;117:603-624.
30. Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol. 1998;125:585-592.
31. Greve EL, Rulo AH, Drance SM, et al. Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: A review of short-term studies with three dose regimens of latanoprost treatment. Surv Ophthalmol. 1997;41:S89-S92.
32. Hoyng PFJ, Rulo A, Greve EL, et al. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Surv Ophthalmol. 1997;41:S93-S98.
33. Widengård I, Mäepea O, Alm A. Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. Br J Ophthalmol. 1998; 82:404-406.
34. Alm A, Widengård I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995;79:12-16.
35. 2α analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78:899-902.
36. Rulo AH, Greve EL, Hoyng PF. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure. Ophthalmology. 1997;104:1503-1507.
37. Vanlandingham BD, Brubaker RF. Combined effect of dorzolamide and latanoprost on the rate of aqueous humor flow. Am J Ophthalmol. 1998;126:191-196.
38. Friström B, Nilsson SEG. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993; 111:662-665.
39. Shin DH, McCracken MS, Bendel RE, et al. The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose and no pilocarpine therapy. Ophthalmology. 1999;106:386-390.
40. 2α. Arch Ophthalmol. 1987;105:1112-1116.
41. 2α on IOP in glaucomatous monkey eyes. Invest Ophthalmol Vis Sci. 1990;31:150 (abstr).
42. Lindén C, Alm A. Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes. Arch Ophthalmol. 1997;115:857-861.
43. Wistrand P, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41:S129-S138.
44. Yamamoto T, Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma. 1997;6:430-432.
45. Zhan G-L, Toris CB, Camras CB, et al. Prostaglandin-induced iris color darkening. An experimental model. Arch Ophthalmol. 1998;116:1065-1068.
46. Selén G, Stjernschantz J, Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol. 1997; 41:S125-S128.
47. Bito LZ. Prostaglandins: A new approach to glaucoma management with a new, intriguing side effect. Surv Ophthalmol. 1997;41:S1-S14.
48. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol. 1997;115:1206-1208.
49. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124:544-547.
50. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998;126:37-41.
51. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review. Ophthalmology. 1998;105:263-268.
52. Camras CB. CME and anterior uveitis with latanoprost use. Ophthalmology. 1998;105:1978-1981.
53. Diestelhorst M, Roters S, Krieglstein GK. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%. Graefes Arch Clin Exp Ophthalmol. 1997;235:20-26.
54. Lindén C, Nuija E, Alm A. Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Ophthalmol. 1997;81:370-372.
55. Miyake K, Ota I, Maekubo K, et al. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999;117:34-40.
56. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol. 1997; 124:683-685.
57. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol. 1998; 126:134-135.
58. Gaddie IB, Bennett DW. Cystoid macular edema associated with the use of latanoprost. J Amer Optom Assoc. 1998;69:122-128.
59. Heier JS, Steinert RF, Frederick AR. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol. 1998;116:680-682.
60. Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol. 1998;116:679-680.
61. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998;126:602-604.
62. Schumer RA, Camras CB, Mandahl A. Occurrence of cystoid macular edema in eyes treated with latanoprost -preliminary analysis. In: Krieglstein GK, ed. Glaucoma Update VI. Heidelberg: Springer-Verlag; in press.
63. Hoyng PFJ, Rulo AH, Greve EL, et al. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: A review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol. 1997;41:S83-S88.
64. Enyedi LB, Freedman SF, Buckley EG. The effectiveness of latanoprost for the treatment of pediatric glaucoma. JAAPOS. 1999;3:33-39.